Cancer immunology

Results: 530



#Item
1The UNM Interdisciplinary HPV Prevention Center

The UNM Interdisciplinary HPV Prevention Center

Add to Reading List

Source URL: hpvprevention.unm.edu

Language: English - Date: 2012-07-09 16:50:03
2VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

Add to Reading List

Source URL: sunstone.eu

Language: English - Date: 2016-07-12 04:22:18
3Cover Conference-at-a-Glance Final Agenda Eighth Annual

Cover Conference-at-a-Glance Final Agenda Eighth Annual

Add to Reading List

Source URL: www.giievent.jp

Language: English - Date: 2016-08-16 03:53:14
4Anticancer ResJan;33(1):Intratumoural interleukin-2 therapy can induce regression of nonresectable mastocytoma in dogs. Ziekman PG1, Otter WD, Tan JF, Teske E, Kirpensteijn J, Koten JW, Jacobs JJ. Author

Anticancer ResJan;33(1):Intratumoural interleukin-2 therapy can induce regression of nonresectable mastocytoma in dogs. Ziekman PG1, Otter WD, Tan JF, Teske E, Kirpensteijn J, Koten JW, Jacobs JJ. Author

Add to Reading List

Source URL: alsterscience.com

Language: English - Date: 2014-12-01 13:50:24
5Press release Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety Mainz, Germany, August 04, A clinical first-in-human Phase I multi center study with GANYMED’s monoclonal anti

Press release Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety Mainz, Germany, August 04, A clinical first-in-human Phase I multi center study with GANYMED’s monoclonal anti

Add to Reading List

Source URL: www.ganymed-pharmaceuticals.com

Language: English - Date: 2015-02-04 05:15:07
6The 7th Barossa Meeting—Cell Signalling in Cancer Biology and Therapy in Barossa Valley, Australia

The 7th Barossa Meeting—Cell Signalling in Cancer Biology and Therapy in Barossa Valley, Australia

Add to Reading List

Source URL: www.centreforcancerbiology.org.au

Language: English - Date: 2016-03-08 23:32:36
7F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

Add to Reading List

Source URL: www.f-star.com

Language: English - Date: 2016-07-13 10:00:22
817427_UKW_AG-Bumm_Postdoc.cdr

17427_UKW_AG-Bumm_Postdoc.cdr

Add to Reading List

Source URL: www.labtimes.org

Language: English - Date: 2016-08-05 06:11:11
9PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell

PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell

Add to Reading List

Source URL: www.immunocore.com

Language: English - Date: 2016-03-29 05:35:06
10KARUPPAIYA ANNAMALAI: Malaysia Radiolabled monoclonal antiobodies for the diagnoses and treament of cancer. Mr. Karuppaiya Annamalai works as a researcher in the Medical Technology Division of the Malaysian Nuclear Agenc

KARUPPAIYA ANNAMALAI: Malaysia Radiolabled monoclonal antiobodies for the diagnoses and treament of cancer. Mr. Karuppaiya Annamalai works as a researcher in the Medical Technology Division of the Malaysian Nuclear Agenc

Add to Reading List

Source URL: international.anl.gov

Language: English - Date: 2010-11-10 12:48:26